Replies to post #3526 on ka<>$H

[$oldier Hard]

CLRX has been good in the past. This from yesterday...
Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50 Issued By BrokerBank Securities, Inc.
7:00a ET February 3, 2015 (PR NewsWire) Print

Littany Lane Investments analyst initiates coverage of CollabRx, Inc. (NASDAQ: CLRX) with near term price target of $2.50-$3.50/share. CollabRx recently announced an LOI to merge with Medytox Solutions on January 22nd, 2015. Medytox could potentially add over $52.5M in annual revenue to CollabRx's bottom line based on the most recent annual report issued by Medytox (Year ending December 31st, 2013).

A full analyst report with a company highlights, description of company products, recent events, outlook, analyst summary, price target and recommendation can be viewed by using link below.

It should be noted that this recent analyst coverage and price target does not include the potential revenues Medytox brings to the table should the merger be completed. There is no cost obligation required to view analyst brief: